TC
ADVM

TFS Capital’s Adverum Biotechnologies ADVM Stock Holding History

TFS Capital’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-8,916
Closed -$241K – 606
2017
Q1 		$241K Buy
8,916
+6,854
+332% +$195K 0.08% 426
2016
Q4 		$60K Sell
2,062
-5,703
-73% -$186K 0.02% 678
2016
Q3 		$319K Sell
7,765
-8,171
-51% -$310K 0.08% 405
2016
Q2 		$504K Buy
15,936
+12,494
+363% +$565K 0.09% 373
2016
Q1 		$178K Buy
+3,442
New +$192K 0.03% 796
2015
Q4 		– Sell
-3,563
Closed -$294K – 736
2015
Q3 		$294K Buy
+3,563
New +$455K 0.03% 668

Other funds holding ADVM

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TFS Capital's ADVM Position: Q2 2017 in Review

TFS Capital sold out of Adverum Biotechnologies (ADVM) in Q2 2017, closing a stake of 8,916 shares — an estimated $241K sold.

TFS Capital first reported a position in ADVM in Q3 2015 and held it in 6 quarters. The position peaked at $504K in Q2 2016. 63 funds tracked by Wall St. Rank hold ADVM as of Q2 2017.

  • TFS Capital reported no remaining Adverum Biotechnologies position as of Q2 2017 after selling out during the quarter.
  • TFS Capital sold 8,916 Adverum Biotechnologies shares in Q2 2017, an estimated $241K.
  • TFS Capital first reported a position in Adverum Biotechnologies in Q3 2015 and held it in 6 quarters.
  • TFS Capital's Adverum Biotechnologies position peaked at $504K in Q2 2016.
  • 63 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2017.

Based on TFS Capital's 13F filing for Q2 2017, filed 11 Aug 2017.